Abstract 356P
Background
Terminal cancer pain continues to be a significant morbidity. Most of the patients need intervention by pain specialists - and few still remain “difficult to treat”. In India, most of these patients do shift to alternative medicine in desperation, with active ingredients, such as steroids/cannabinoids, and few unclassified anti-tumor substances. After listing and analyzing these the two most frequently observed ones are steroids and cannabinoids wherever patients have satisfactory pain control.
Methods
An interview based study was conducted as a part of QOL Data collection, which included other symptoms (such as fatigue, cachexia, well-being etc.) in the period of 2016-2018. One of key inclusions was - patients with advanced cancer progressed on multiple lines for which there was no standard of care. After data collection, a subset analysis was conducted with reference to pain control and use of alternative medication. For ease of analysis subjects were grouped into 4 categories based on pain control with opioids and concurrent use of cannabinoids. Subjects whose nature of the medication was not known were excluded. All four groups were analyzed for the pain control with help of visual analogy scale (VAS).
Results
The baseline demographic characters in all four groups were well balanced and depicted in Table -1. Overall there were no statistically significant differences in the duration of symptoms, average dose of opioid analgesia, performance status and the stage of disease. Pain relief was better in the cannabis group, when it was used independently or in combination with opioids. No significant additional side effects pertaining to cannabis were reported by the patients. The overall qualities of life, as well as weight gain and nausea control were better in the cannabis group.
Conclusions
We could infer that Bhang [cannabis crude form], is an effective analgesic independently having synergy with opioids. It also improved overall QOL, especially in cachexia, without adverse effects. If scientifically proven with pharmaceutical grade, it will be a significant addition to the symptomatic care of terminally ill cancer patients. Though available in US, India still does not have regulatory approval for medical cannabis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract